摘要
目的研究重组人干扰素α1b雾化治疗毛细支气管炎的临床效果。方法 150例毛细支气管炎患儿,随机分为常规组及干扰素组,各75例。常规组采用常规抗感染以及抗病毒药物进行干预,干扰素组在常规组基础上增加重组人干扰素α1b雾化治疗。比较两组患儿毛细支气管炎治疗效果,治疗前和治疗5 d后患儿肺功能指标[第一秒用力呼气容积(FEV1)、用力肺活量(FVC)]的差异,哮鸣音消失时间、湿啰音消失时间、憋喘持续时间、咳嗽持续时间。结果干扰素组患儿总有效率97.33%高于常规组84.00%,差异具有统计学意义(χ~2=7.878,P<0.05)。治疗前,两组患儿的FEV1、FVC比较,差异均无统计学意义(P>0.05);治疗5 d后,两组患儿的FEV1、FVC均较治疗前升高,且干扰素组高于常规组,差异均具有统计学意义(P<0.05)。干扰素组患儿的哮鸣音消失时间、湿啰音消失时间、憋喘持续时间、咳嗽持续时间均短于常规组,差异均具有统计学意义(t=2.452、2.081、6.029、5.369,P<0.05)。结论重组人干扰素α1b雾化治疗毛细支气管炎的临床效果确切,可有效改善患儿病情,加速临床症状消退,改善肺功能,值得推广应用。
Objective To study the clinical effect of recombinant human interferonα1b nebulizer therapy in capillary bronchitis.Methods A total of150capillary bronchitis children were randomly divided into conventional group and interferon group,with75cases in each group.The conventional group received routine anti-infection and antiviral drugs for intervention,and the interferon group received recombinant human interferonα1b nebulizer therapy on the basis of the conventional group.Comparison were made on treatment effect,lung function index[forced expiratory volume in1second(FEV1)and forced vital capacity(FVC)]difference before treatment and5d of treatment,wheezing rale and moist rale disappearance time,asthma and cough duration in two groups.Results The interferon group had higher total effective rate as97.33%than84.00%in the conventional group,and the difference had statistical significance(χ2=7.878,P<0.05).Before treatment,both groups had no statistically significant difference in FEV1and FVC(P>0.05).After5d of treatment,both groups had higher FEV1and FVC than before treatment,and the interferon group was higher than the conventional group.Their difference had statistical significance(P<0.05).The interferon group had shorter wheezing rale disappearance time,moist rale disappearance time,asthma duration and cough duration than the conventional group,and theirdifference had statistical significance(t=2.452,2.081,6.029,5.369,P<0.05).Conclusion Recombinant human interferonα1b nebulizer therapy shows affirmative clinical effect in capillary bronchitis,which can effectively improve pathogenetic condition,speed disappearance of clinical symptoms and improve lung function.So it is worth promotion and application.
作者
张彩艳
孙文莉
ZHANG Cai-yan;SUN Wen-li(Department of Pediatrics, Xinjiang Shihezi City People’s Hospital,Shihezi 832003, China)
出处
《中国现代药物应用》
2017年第6期34-36,共3页
Chinese Journal of Modern Drug Application
关键词
重组人干扰素Α1B
雾化治疗
毛细支气管炎
临床效果
Recombinant human interferon α1b
Nebulizer therapy
Capillary bronchitis
Clinical effect
